Dynamic Thyroglobulin Ratio as a Biomarker to Identify Papillary Thyroid Cancer Patients Who Would Benefit from a Low-Iodine Diet.
: This study aimed to assess whether low-iodine diet (LID) adherence is associated with therapeutic response in papillary thyroid carcinoma (PTC), specifically in relation to post-therapeutic thyroglo
- 95% CI 1.270-3.162
APA
Yoo SW, Na YM, et al. (2026). Dynamic Thyroglobulin Ratio as a Biomarker to Identify Papillary Thyroid Cancer Patients Who Would Benefit from a Low-Iodine Diet.. Diagnostics (Basel, Switzerland), 16(3). https://doi.org/10.3390/diagnostics16030456
MLA
Yoo SW, et al.. "Dynamic Thyroglobulin Ratio as a Biomarker to Identify Papillary Thyroid Cancer Patients Who Would Benefit from a Low-Iodine Diet.." Diagnostics (Basel, Switzerland), vol. 16, no. 3, 2026.
PMID
41681776
Abstract
: This study aimed to assess whether low-iodine diet (LID) adherence is associated with therapeutic response in papillary thyroid carcinoma (PTC), specifically in relation to post-therapeutic thyroglobulin (Tg) release as a surrogate marker for the acute radiation-induced response following radioactive iodine (RAI) therapy. : This retrospective study included 895 patients with PTC treated with RAI. LID adherence was assessed using the urine iodine-to-creatinine (I/Cr) ratio, with <66.2 μg/g Cr defined as good adherence. The Tg ratio (ratioTg), calculated by dividing post-RAI Tg (measured 7 days after RAI) by pre-RAI Tg, was used to reflect the magnitude of the radiation-induced Tg release. Patients were stratified by ratioTg (≤1 vs. >1), and associations between LID adherence and therapeutic response were analyzed within each group. : Well-adherent patients exhibited significantly higher ratioTg compared to poorly adherent patients (15.7 ± 2.2 vs. 8.9 ± 1.3, = 0.007). Among patients with ratioTg > 1 ( = 630), LID adherence was independently associated with improved therapeutic response (OR, 2.004; 95% CI, 1.270-3.162; = 0.003). No such association was observed in patients with ratioTg ≤ 1 ( = 265; = 0.546). : The clinical benefit of LID appears to depend on the presence of a certain magnitude of radiation-induced Tg release. RatioTg may serve as a useful marker for identifying patients likely to benefit from LID.